Relative effectiveness of letrozole compared with tamoxifen for patients with lobular carcinoma in the BIG 1-98 Trial

Otto Metzger Filho, Anita Giobbie-Hurder, Elizabeth Mallon, Barry Gusterson, Giuseppe Viale, Eric P. Winer, Beat Thürlimann, Richard D. Gelber, Marco Colleoni, Bent Ejlertsen, Marc Debled, Karen N. Price, Meredith M. Regan, Alan S. Coates, Aron Goldhirsch

Research output: Contribution to journalArticle

Abstract

Purpose To evaluate the relative effectiveness of letrozole compared with tamoxifen for patients with nvasive ductal or lobular carcinoma Patients and Methods Patients diagnosed with early-stage invasive ductal carcinoma (IDC) or classic invasive lobular carcinoma (ILC) who were randomly assigned onto the Breast International Group (BIG) 1-98 tria and who had centrally reviewed pathology data were included (N = 2,923). HER2-negative IDC and LC were additionally classified as hormone receptor-positive with high (luminal B [LB] -like) or low (luminal A [LA] -like) proliferative activity by Ki-67 labeling index. Survival analyses were performed with weighted Cox models that used inverse probability of censoring weighted modeling Results The median follow-up time was 8.1 years. In multivariable models for disease-free survival (DFS), significant interactions between treatment and histology (ILC or IDC; P = .006) and treatment and subgroup (LB like or LA like; P = .01) were observed. In the ILC subset, there was a 66% reduction in the hazard of a DFS event with letrozole for LB (hazard ratio [HR], 0.34; 95% CI, 0.21 to 0.55) and a 50% reduction for LA subtypes (HR, 0.50; 95% CI, 0.32 to 0.78). In the IDC subset, there was a significant 35% reduction in the hazard of a DFS event with letrozole forthe LB subtype (HR, 0.65; 95% CI, 0.53 to 0.79), but no difference between treatments was noted for IDC and the LA subtype (HR, 0.95; 95% CI, 0.76 to 1.20) Conclusion The magnitude of benefit of adjuvant letrozole is greater for patients diagnosed with lobular carcinoma versus ductal carcinoma.

Original languageEnglish
Pages (from-to)2772-2778
Number of pages7
JournalJournal of Clinical Oncology
Volume33
Issue number25
DOIs
Publication statusPublished - Sep 1 2015

Fingerprint

letrozole
Lobular Carcinoma
Ductal Carcinoma
Tamoxifen
Breast
Disease-Free Survival
Survival Analysis
Proportional Hazards Models
Histology

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Relative effectiveness of letrozole compared with tamoxifen for patients with lobular carcinoma in the BIG 1-98 Trial. / Filho, Otto Metzger; Giobbie-Hurder, Anita; Mallon, Elizabeth; Gusterson, Barry; Viale, Giuseppe; Winer, Eric P.; Thürlimann, Beat; Gelber, Richard D.; Colleoni, Marco; Ejlertsen, Bent; Debled, Marc; Price, Karen N.; Regan, Meredith M.; Coates, Alan S.; Goldhirsch, Aron.

In: Journal of Clinical Oncology, Vol. 33, No. 25, 01.09.2015, p. 2772-2778.

Research output: Contribution to journalArticle

Filho, OM, Giobbie-Hurder, A, Mallon, E, Gusterson, B, Viale, G, Winer, EP, Thürlimann, B, Gelber, RD, Colleoni, M, Ejlertsen, B, Debled, M, Price, KN, Regan, MM, Coates, AS & Goldhirsch, A 2015, 'Relative effectiveness of letrozole compared with tamoxifen for patients with lobular carcinoma in the BIG 1-98 Trial', Journal of Clinical Oncology, vol. 33, no. 25, pp. 2772-2778. https://doi.org/10.1200/JCO.2015.60.8133
Filho, Otto Metzger ; Giobbie-Hurder, Anita ; Mallon, Elizabeth ; Gusterson, Barry ; Viale, Giuseppe ; Winer, Eric P. ; Thürlimann, Beat ; Gelber, Richard D. ; Colleoni, Marco ; Ejlertsen, Bent ; Debled, Marc ; Price, Karen N. ; Regan, Meredith M. ; Coates, Alan S. ; Goldhirsch, Aron. / Relative effectiveness of letrozole compared with tamoxifen for patients with lobular carcinoma in the BIG 1-98 Trial. In: Journal of Clinical Oncology. 2015 ; Vol. 33, No. 25. pp. 2772-2778.
@article{29eeab8f01cd4a3daf8c0b6d048eb801,
title = "Relative effectiveness of letrozole compared with tamoxifen for patients with lobular carcinoma in the BIG 1-98 Trial",
abstract = "Purpose To evaluate the relative effectiveness of letrozole compared with tamoxifen for patients with nvasive ductal or lobular carcinoma Patients and Methods Patients diagnosed with early-stage invasive ductal carcinoma (IDC) or classic invasive lobular carcinoma (ILC) who were randomly assigned onto the Breast International Group (BIG) 1-98 tria and who had centrally reviewed pathology data were included (N = 2,923). HER2-negative IDC and LC were additionally classified as hormone receptor-positive with high (luminal B [LB] -like) or low (luminal A [LA] -like) proliferative activity by Ki-67 labeling index. Survival analyses were performed with weighted Cox models that used inverse probability of censoring weighted modeling Results The median follow-up time was 8.1 years. In multivariable models for disease-free survival (DFS), significant interactions between treatment and histology (ILC or IDC; P = .006) and treatment and subgroup (LB like or LA like; P = .01) were observed. In the ILC subset, there was a 66{\%} reduction in the hazard of a DFS event with letrozole for LB (hazard ratio [HR], 0.34; 95{\%} CI, 0.21 to 0.55) and a 50{\%} reduction for LA subtypes (HR, 0.50; 95{\%} CI, 0.32 to 0.78). In the IDC subset, there was a significant 35{\%} reduction in the hazard of a DFS event with letrozole forthe LB subtype (HR, 0.65; 95{\%} CI, 0.53 to 0.79), but no difference between treatments was noted for IDC and the LA subtype (HR, 0.95; 95{\%} CI, 0.76 to 1.20) Conclusion The magnitude of benefit of adjuvant letrozole is greater for patients diagnosed with lobular carcinoma versus ductal carcinoma.",
author = "Filho, {Otto Metzger} and Anita Giobbie-Hurder and Elizabeth Mallon and Barry Gusterson and Giuseppe Viale and Winer, {Eric P.} and Beat Th{\"u}rlimann and Gelber, {Richard D.} and Marco Colleoni and Bent Ejlertsen and Marc Debled and Price, {Karen N.} and Regan, {Meredith M.} and Coates, {Alan S.} and Aron Goldhirsch",
year = "2015",
month = "9",
day = "1",
doi = "10.1200/JCO.2015.60.8133",
language = "English",
volume = "33",
pages = "2772--2778",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "25",

}

TY - JOUR

T1 - Relative effectiveness of letrozole compared with tamoxifen for patients with lobular carcinoma in the BIG 1-98 Trial

AU - Filho, Otto Metzger

AU - Giobbie-Hurder, Anita

AU - Mallon, Elizabeth

AU - Gusterson, Barry

AU - Viale, Giuseppe

AU - Winer, Eric P.

AU - Thürlimann, Beat

AU - Gelber, Richard D.

AU - Colleoni, Marco

AU - Ejlertsen, Bent

AU - Debled, Marc

AU - Price, Karen N.

AU - Regan, Meredith M.

AU - Coates, Alan S.

AU - Goldhirsch, Aron

PY - 2015/9/1

Y1 - 2015/9/1

N2 - Purpose To evaluate the relative effectiveness of letrozole compared with tamoxifen for patients with nvasive ductal or lobular carcinoma Patients and Methods Patients diagnosed with early-stage invasive ductal carcinoma (IDC) or classic invasive lobular carcinoma (ILC) who were randomly assigned onto the Breast International Group (BIG) 1-98 tria and who had centrally reviewed pathology data were included (N = 2,923). HER2-negative IDC and LC were additionally classified as hormone receptor-positive with high (luminal B [LB] -like) or low (luminal A [LA] -like) proliferative activity by Ki-67 labeling index. Survival analyses were performed with weighted Cox models that used inverse probability of censoring weighted modeling Results The median follow-up time was 8.1 years. In multivariable models for disease-free survival (DFS), significant interactions between treatment and histology (ILC or IDC; P = .006) and treatment and subgroup (LB like or LA like; P = .01) were observed. In the ILC subset, there was a 66% reduction in the hazard of a DFS event with letrozole for LB (hazard ratio [HR], 0.34; 95% CI, 0.21 to 0.55) and a 50% reduction for LA subtypes (HR, 0.50; 95% CI, 0.32 to 0.78). In the IDC subset, there was a significant 35% reduction in the hazard of a DFS event with letrozole forthe LB subtype (HR, 0.65; 95% CI, 0.53 to 0.79), but no difference between treatments was noted for IDC and the LA subtype (HR, 0.95; 95% CI, 0.76 to 1.20) Conclusion The magnitude of benefit of adjuvant letrozole is greater for patients diagnosed with lobular carcinoma versus ductal carcinoma.

AB - Purpose To evaluate the relative effectiveness of letrozole compared with tamoxifen for patients with nvasive ductal or lobular carcinoma Patients and Methods Patients diagnosed with early-stage invasive ductal carcinoma (IDC) or classic invasive lobular carcinoma (ILC) who were randomly assigned onto the Breast International Group (BIG) 1-98 tria and who had centrally reviewed pathology data were included (N = 2,923). HER2-negative IDC and LC were additionally classified as hormone receptor-positive with high (luminal B [LB] -like) or low (luminal A [LA] -like) proliferative activity by Ki-67 labeling index. Survival analyses were performed with weighted Cox models that used inverse probability of censoring weighted modeling Results The median follow-up time was 8.1 years. In multivariable models for disease-free survival (DFS), significant interactions between treatment and histology (ILC or IDC; P = .006) and treatment and subgroup (LB like or LA like; P = .01) were observed. In the ILC subset, there was a 66% reduction in the hazard of a DFS event with letrozole for LB (hazard ratio [HR], 0.34; 95% CI, 0.21 to 0.55) and a 50% reduction for LA subtypes (HR, 0.50; 95% CI, 0.32 to 0.78). In the IDC subset, there was a significant 35% reduction in the hazard of a DFS event with letrozole forthe LB subtype (HR, 0.65; 95% CI, 0.53 to 0.79), but no difference between treatments was noted for IDC and the LA subtype (HR, 0.95; 95% CI, 0.76 to 1.20) Conclusion The magnitude of benefit of adjuvant letrozole is greater for patients diagnosed with lobular carcinoma versus ductal carcinoma.

UR - http://www.scopus.com/inward/record.url?scp=84941332235&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941332235&partnerID=8YFLogxK

U2 - 10.1200/JCO.2015.60.8133

DO - 10.1200/JCO.2015.60.8133

M3 - Article

AN - SCOPUS:84941332235

VL - 33

SP - 2772

EP - 2778

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 25

ER -